CLAIMS

1. A pharmaceutical composition comprising a nanoparticle composition, a known therapeutic agent or independently active biologically active agent and at least one excipient,

wherein the nanoparticle composition comprises a population of particles, wherein the majority of particles have diameters between 10 and 300 nanometers,

wherein the nanoparticle composition comprises at least one aqueous dispersion medium, at least one oil, and at least one surfactant,

wherein the oil is a medium chain triglyceride,

wherein the surfactant is a polysorbate,

wherein the ratio of oil to surfactant is between about 0.5:1 to about 1:1; and,

wherein the at least one excipient is mineral oil, isopropyl myristate, white petrolatum, emulsifying wax, propyl paraben, methyparaben, or any combination thereof,

wherein the pharmaceutical composition has a degree of transdermal penetration higher than when said at least one excipient is absent.

2. The pharmaceutical composition of claim 1, wherein the medium chain triglyceride is an acid containing 6-12 carbons atoms or is Labracfac Lipophile WL 1349 oil.

3. The pharmaceutical composition of claim 1, wherein the polysorbate is polysorbate 80.

4. The pharmaceutical composition of any one of claims 1-3, wherein the pharmaceutical composition does not contain parabens.

5. The pharmaceutical composition of any one of claims 1-4, wherein the known therapeutic agent or independently active biologically active agent is a protein, an antibody, a protein complex or a combination thereof, or wherein the known therapeutic agent or independently active biologically active agent is botulinum toxin.

6. The pharmaceutical composition of claim 5, wherein the botulinum toxin is selected from the group comprising type A, type Ab, type Af, type B, type Bf, type C1, type C2, type D, type E, type F, type G, and any combinations thereof, optionally the botulinum toxin is type A botulinum toxin.

7. The pharmaceutical composition of any one of claims 1-6, wherein the pharmaceutical composition is formulated for topical administration, parenteral administration or oral administration.

8. The pharmaceutical composition of claim 7, wherein the pharmaceutical composition formulated for topical administration can

(i) penetrate skin without altering or changing the skin;

(ii) penetrate skin without the use of skin permeation enhancers or abrasives;

(iii) penetrate the top layer of skin without the use of skin permeation enhancers or abrasives; or combination thereof,

optionally wherein the top layer of the skin

(a) is the surface of the stratum corneum;

(b) includes dermal pores;

(c) includes dermal glands; or any combination thereof.

9. The pharmaceutical composition of claim 7, wherein the pharmaceutical composition is formulated as a liquid dosage form or formulated as a sterile injectable formulation.

10. The pharmaceutical composition of claim 7, wherein the pharmaceutical composition remains stable following prolonged storage, wherein the prolonged storage is at least 1 week, at least 2 weeks, at least 1 month, at least 2 months, at least 3 months, at least 6 months, at least 9 months, or at least 12 months, optionally wherein the prolonged storage is carried out at 2 °C to 8 °C.

11. A kit comprising the pharmaceutical composition of any one of claims 1-6.

12. Use of the pharmaceutical composition of any one of claims 1-6 in the manufacture of ~~a~~an medicament for treatment of:

(i) (a) a condition or disorder associated with sebaceous glands;

(b) a condition or disorder associated with sweat glands;

(c) a condition or disorder associated with hair follicles; the outer layer of the skin; or any combination thereof or

(ii) a condition or disorder selected from the group consisting of acne, hyperhidrosis, unwanted sweating, bromhidrosis, body odor, chromhidrosis, excess sebum-producing disorders, seborrhea, seborrheic dermatitis, rosacea, hair loss, psoriasis, dermal infections, viral infection, bacterial infection, fungal infection, actinic keratosis, eczematous dermatitis, atopic dermatitis, burns, Raynaud's phenomenon, lupus erthythematosus, hyperpigmentation disorders, melasma, hypopigmentation disorders, vitiligo, skin cancer, squamous cell skin carcinoma, basal cell skin carcinoma, arthritis, osteoarthritis, bruxism, cervical neck pain, dry eyes, gastrointestinal disorders, achalasia, esophageal spasm, gastroparesis, spasm of the sphincter of oddi, anal fissure, anismus, lateral epicondylitis, back pain, lower back pain, upper back pain, masseter muscle hypertrophy, facial nerve disorders~~, facial wrinkles, wrinkles involving the forehead, glabellar, rhytids and/or periorbital regions, unsightly facial expressions, neck lines, hyperfunctional facial lines, hyperkinetic facial lines, platysma bands~~, neuromuscular disorders and conditions involving muscular spasm or contracture, facial palsy such as hemi facial spasm, cerebral palsy, spasticisty due to stroke, blepharospasm, facial contracture, dystonia, cervical dystonia, laryngeal dystonia, oromandibular dystonia, writer's cramp, neuralgias, trigeminal neuralgia, neuropathic pain, Parkinson's disease, plantar fasciitis pain, prostate hyperplasia, headache, migraine, essential headache, cervicogenic headache, tension headache, prostatic disorders, prostatic pain, prostatic hypertrophy, restless leg syndrome, rhinitis, allergic rhinitis, sialorrhea, skin pruritis, strabismus, temporomandibular joint ("TMJ") syndrome, tics, Tourette's syndrome, hemifacial spasm, tremor, essential tremor, urinary bladder dysfunction, detrusor sphincter dysnergia, painful bladder, bladder spasticity, overactive bladder, vaginismus, spasticity such as that resulting from multiple sclerosis, retroorbital muscle, various ophthalmologic conditions, and/or combinations thereof, or

(iii) unwanted sweating, bromhidrosis, body odor, chromhidrosis, acne, wrinkles, headache, or any combination thereof.

13. The use of claim 12, wherein the pharmaceutical composition is to be administered via a route of delivery selected from the group consisting of oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, subcutaneous, intraventricular, transdermal, interdermal, intradermal, rectal, vaginal, intraperitoneal, intragastric, topical, mucosal, intranasal, buccal, enteral, vitreal, sublingual, and combinations thereof.

14. The use of claim 12, wherein the pharmaceutical composition is to be administered via a route of delivery selected from the group consisting of intratracheal instillation, bronchial instillation, inhalation, and combinations thereof.

15. Use of the pharmaceutical composition of any one of claims 1-6 for treating a cosmetic condition selected from the group consisting of facial wrinkles, wrinkles involving the forehead, glabellar, rhytids and/or periorbital regions, unsightly facial expressions, neck lines, hyperfunctional facial lines, hyperkinetic facial lines, and platysma bands.